Abstract
Legionella pneumophila is the most common cause of the severe respiratory infection known as Legionnaires' disease. However, the microorganism is typically a symbiont of free-living amoeba, and our understanding of the bacterial factors that determine human pathogenicity is limited. Here we carried out a population genomic study of 902 L. pneumophila isolates from human clinical and environmental samples to examine their genetic diversity, global distribution and the basis for human pathogenicity. We find that the capacity for human disease is representative of the breadth of species diversity although some clones are more commonly associated with clinical infections. We identified a single gene (lag-1) to be most strongly associated with clinical isolates. lag-1, which encodes an O-acetyltransferase for lipopolysaccharide modification, has been distributed horizontally across all major phylogenetic clades of L. pneumophila by frequent recent recombination events. The gene confers resistance to complement-mediated killing in human serum by inhibiting deposition of classical pathway molecules on the bacterial surface. Furthermore, acquisition of lag-1 inhibits complement-dependent phagocytosis by human neutrophils, and promoted survival in a mouse model of pulmonary legionellosis. Thus, our results reveal L. pneumophila genetic traits linked to disease and provide a molecular basis for resistance to complement-mediated killing.
Introduction
Legionella pneumophila is the primary cause of Legionnaires' disease, a severe and often fatal pneumonia. Curiously, this bacterium is naturally a symbiont of freshwater amoebae; human infection is essentially an "accidental" biological dead-end. For over 30 years, scientists have known that a specific subgroup (Serogroup 1) causes more than 85% of human cases, and some strains are much better at resisting human immune responses than others. However, the exact genetic "smoking gun" responsible for this enhanced pathogenicity remained a mystery. This study identifies the specific genetic traits that allow certain environmental Legionella strains to successfully jump into human hosts and survive the innate immune system.
Population Genomics and Dataset
To understand the evolutionary landscape of the species, a massive dataset of 902 L. pneumophila isolates was analyzed. This included 397 isolates from the Scottish Microbiology Reference Laboratory (SHLMPRL) spanning 1984 to 2015, and 500 assembled genomes from public databases. This collection represents one of the most comprehensive genomic snapshots of the species to date, covering seven major phylogenetic clades.
The phylogenetic analysis revealed that clinical isolates are distributed across the entire breadth of the species' diversity, though certain clades and clones show a higher frequency of association with human disease.
Identification of the Pathogenicity Factor lag-1
The researchers employed a population genomics approach using Genome-Wide Association Study (GWAS) tools, specifically SEER and SCOARY, to compare clinical isolates against environmental ones. Out of over 11,000 accessory genes, lag-1 showed the strongest statistical association with human disease.
lag-1 was found in 80.1% of clinical isolates but only 30.8% of environmental isolates. It encodes an O-acetyltransferase that modifies the lipopolysaccharide (LPS) on the bacterial surface. Interestingly, lag-1 has moved horizontally across all major clades of the species via frequent recombination events, suggesting it provides a significant selective advantage for human infection.
Mechanism of Immune Evasion
Functional validation experiments demonstrated that lag-1 specifically blocks the classical complement pathway. By modifying the LPS, the bacteria prevent the deposition of C3 proteins—the "molecular tags" the immune system uses to identify and kill invaders. Strains lacking lag-1 were rapidly killed by human plasma, while those expressing it showed high survival rates.
Furthermore, resistance to complement prevents neutrophils from recognizing and "eating" the bacteria (phagocytosis). In a mouse model of pulmonary legionellosis, lag-1 expressing strains showed a significantly higher bacterial burden in the lungs 96 hours post-infection compared to strains lacking the gene.
Conclusion
This study identifies lag-1 as a primary driver behind L. pneumophila's ability to cause severe pneumonia. By inhibiting the human complement system, lag-1 allows the pathogen to evade both blood-borne killing and phagocytosis. While lag-1 is a major factor, it does not explain 100% of clinical cases, suggesting other genetic factors may also contribute to pathogenicity. Future work is needed to understand the role of lag-1 in the natural environment and the triggers for its phase variation.
Summary updated